Groundbreaking insights from the 9th Cardiovascular Outcome Trial (CVOT) Summit

Illustration of a human heart

Don’t miss out on groundbreaking insights from the 9th Cardiovascular Outcome Trial (CVOT) Summit! Our Chief Medical Officer, Thomas Forst, Prof. Dr., collaborated with global leaders in endocrinology, cardiology, diabetology, nephrology, and more to discuss recent trial outcomes. This virtual summit showcased advancements in cardiovascular risk reduction, metabolic outcomes improvement, and obesity-related heart failure treatment. Moreover, […]

New Study: „Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug-drug interactions“

medical illustration of a human liver

Ever wondered how chronic liver diseases impact medication effectiveness? The study „Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug-drug interactions“ conducted by Dr. Sara Armani and Thomas Forst, Prof. Dr. (in collaboration with our partners from around the world) delves into this crucial topic. Their […]

Critical insights: Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes

Mannheim, Germany, March 18th 2024 –  Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). This clinical trial, conducted on both healthy volunteers and individuals with T2D, underscores the safety of ATR-258 […]

Check out the study “First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.”

First-in-human study of eliapixant (BAY 1817080)

Have you already read this interesting publication on PubMed? 📑 📢 Check out the study “First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the publication here: https://pubmed.ncbi.nlm.nih.gov/35437837/

Check out the study “Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis”

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis

Have you already read this interesting publication on ERJ Open Research? 📑 📢 Check out the study “Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the […]

Check out the study “Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment”

Check out the study “Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment”

Have you already read this interesting publication on Scientific Reports? 📑 📢 Check out the study “Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the publication here: https://www.nature.com/articles/s41598-022-22470-z

Check out the study “Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant”

Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant

Have you already read this interesting publication on PubMed? 📑 📢 Check out the study “Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the […]

Check out the study “Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment”

Check out the study “Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment”

Have you already read this interesting publication on PubMed? 📑 📢 Check out the study “Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the publication here: https://pubmed.ncbi.nlm.nih.gov/36786053/

Check out the study “Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity”

CRS’s Expertise

Have you already read the latest publication on PubMed ? Check out the study “Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the publication here: […]

New Whitepaper: New strategies to improve clinical outcomes for diabetic kidney disease

Diabetes is a significant challenge for the global healthcare system: The International Diabetes Federation (IDF) estimates that healthcare expenditures already amount to USD 966 billion. In the coming years, the number of diabetics is expected to continue to increase significantly, and by 2045 it is estimated that 783 million people worldwide be living with the […]